Skip to content
Review Open access

From signal to survival

TL;DR

This thesis shows how computational methods can aid, automate and augment the analysis of immunophenotypic characteristics in AML, enabling the translation from measurements to prognosis and outcomes (survival).

Abstract

Acute myeloid leukemia (AML) is a heterogeneous myeloid neoplasm characterized by uncontrolled proliferation of immature myeloid blasts. Although most patients treated with intensive chemotherapy can achieve a state of morphological remission, residual leukemic cells may remain in the bone marrow and are associated with relapse. Different assays have been developed to detect this measurable residual disease (MRD). One of these techniques, flow cytometry, is widely applicable for AML patients. However, data analysis is based on manual gating, a laborious and potentially subjective process that hampers widespread adoption of flow cytometry-based assays outside specialized centers. This thesis is split into three parts (Part I - III), each focusing on crucial aspects of flow cytometry data analysis in the translational setting. In Part I, we focus on aspects related to pre-processing and quality control of flow cytometry data. The broad implementation of flow cytometry in translational research now results in datasets that can comprise thousands of measurements. For such datasets, manual quality control is close to impossible. To address this, we developed a software package called CytoScan in Chapter 2 for visualization and inspection of large cytometry cohorts, with a particular emphasis on anomaly detection. Limitations in flow cytometry equipment also often require the distribution of different markers across multiple tubes. When shared backbone markers are present, these can be used to calculate or impute missing markers and allow for a combined analysis of complete set of markers for all cells. In Chapter 3, we show that the data generated by such imputation methods is of insufficient quality for use in clinical settings. In Part II, we focus on computational measurable residual disease (cMRD) assessment. In Chapter 4, we review the current landscape of computational methods for AML-MRD assessment. We highlight how the heterogeneity of immunophenotypic patterns and the rarity of leukemic blasts in the MRD setting pose challenges for existing algorithms. Next, in Chapter 5, we propose a novel methodology based on Gaussian mixture models (GMMs) that allows for a fully automated MRD assessment in three seconds per sample. By combining an element of supervised learning for blast identification with GMM-based novelty detection, we effectively reproduce the philosophy behind the existing diagnostic workflow. In Chapter 6, we clinically validate this method in a retrospective cohort of 399 AML patients and find that like manual gating, cMRD is prognostic for outcomes of AML patients. Computational cytometry data analysis is not restricted to automating established manual gating procedures but also benefits from unsupervised analyses that capture distinct characteristics in the data. In Part III, we extend the default GMM architecture to allow for improved modeling of heterogeneous patient cohorts that are typical for AML (Chapter 7). We apply this new algorithm, MSGMM, in an extensive study of the immunophenotypic characteristics of newly diagnosed AML patients in Chapter 8. Taken together, this thesis shows how computational methods can aid, automate and augment the analysis of immunophenotypic characteristics in AML, enabling the translation from measurements (signal) to prognosis and outcomes (survival).

Read PDF

Similar papers

Open access Sep 2026

Indication for FLT3 and CD34 Among Acute Myeloid Leukemia in Sudanese Patients

M Males were less than females, CD34 was detected among 21% and FLT3 mutation detected among 18% as wild, those considered as poor prognosis phase, and MPFC applicable to more than 90% of AML cases, offering broad utility compared with PCR-based molecular MRD testing.

Mohammed Fathi Ibrahim Madani, F. Gameel, M. A. Abdalla et al. · 0 citations
Open access Sep 2026

Prognostic Significance of CD7 Expression in Acute Myeloid Leukemia.

CD7 is expressed in a substantial portion of AML patients and high levels of this lymphoid marker correlate with incomplete remission following induction therapy, which portending poor prognosis.

Sarab M. Hesham, H. Al-Rubaie · 0 citations
Review Open access Sep 2026

Recent Advances in Chronic Myeloid Leukaemia (CML): Emerging Molecular and Immunotherapeutic Targets.

The pivotal role of LSCs in disease progression and relapse is highlighted, potential molecular and epigenetic regulators as new targets for intervention are evaluated, and the development of combination treatment strategies to improve TFR rates and move towards curative outcomes is supported.

Jing-Yi Dai, Pan-Pan Zheng, Jian Liu et al. · 0 citations
Open access Sep 2026

Detection MN1 Gene Expression in Sudanese Patients Diagnosed with Acute Myeloid Leukemia (AML)

Background: The unchecked growth of immature blood cells in the bone marrow is the hallmark of acute leukemia, a potentially fatal hematologic cancer. The burden of acute leukemia is exacerbated in low-resource environments like Sudan by a lack of thorough cancer registries, regional healthcare inequities, and inadequa...

Mohammed Fathi Ibrahim Madani, F. Gameel, M. A. Abdalla et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.